These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33740926)

  • 41. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
    Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
    Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastrointestinal stromal tumor: a review of current and emerging therapies.
    Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
    Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New therapeutic agents in gastrointestinal stromal tumours.
    Falkenhorst J; Hamacher R; Bauer S
    Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
    Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
    Front Immunol; 2020; 11():851. PubMed ID: 32670260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
    Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
    Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
    Bauer S; George S; von Mehren M; Heinrich MC
    Front Oncol; 2021; 11():672500. PubMed ID: 34322383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
    Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G
    Genet Med; 2015 May; 17(5):391-5. PubMed ID: 25188872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
    Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
    Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report.
    Teranishi R; Takahashi T; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
    Surg Case Rep; 2023 Apr; 9(1):54. PubMed ID: 37027098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.